Inotek Pharmaceuticals – $40 Million IPO

New York – February 23, 2015 – Cooley advised the underwriters on Inotek Pharmaceuticals’ $40 million initial public offering of 6,667,000 shares of its common stock. The company now trades on The NASDAQ Global Market under the symbol “ITEK."

Cowen and Company and Piper Jaffray acted as joint book-running managers of the common stock offering and Canaccord Genuity and Nomura Securities International acted as co-managers of the common stock offering. Inotek is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.

Inotek is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. 

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Babak Yaghmaie Partner, New York
Mark Weeks Partner, Palo Alto
Div Gupta Partner, New York
Mischi a Marca Partner, San Francisco
Natasha Leskovsek Partner, Washington, DC
Wendy Goldstein Partner, New York
Susan Cooper Philpot Retired Partner, San Francisco
Matthew Pavao Partner, Boston
Phil Mitchell Partner, New York
Jason Savich Partner, San Francisco